What the science actually tells us about everyday chemical exposure, hormone health, and the changes worth making. If you spend enough time on social media, you'll probably encounter two very different messages about chemicals in everyday products. One says that endocrine-disrupting chemicals are everywhere, poisoning our bodies, and causing everything from infertility to obesity. The other says that concerns about plastics, pesticides, and household chemicals are overblown, and that the amounts we're exposed to are too small to matter. Neither explanation tells the whole story. Endocrine-disrupting chemicals (EDCs) are real, and decades of research have established that certain chemicals can interfere with the body's hormonal systems. Organizations including the Endocrine Society, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists recommend taking reasonable steps to reduce exposure, particularly during pregnancy and early childhood. At the same time, much of the research connecting these chemicals to specific human diseases is observational. We have good evidence that changing certain habits can reduce the amount of some chemicals measured in our bodies, but considerably less evidence that these changes prevent or reverse long-term health problems. And despite what the wellness industry would have you believe, there's no convincing evidence that juice cleanses, detox supplements, sauna sessions, or expensive protocols can meaningfully eliminate endocrine disruptors from your body. So what actually matters? And what is worth doing? What are endocrine-disrupting chemicals? Your endocrine system is a network of glands and hormones that regulates nearly every aspect of your health, including metabolism, growth, reproduction, sleep, and development. Hormones act as chemical messengers, carrying instructions between different parts of your body. Endocrine-disrupting chemicals are substances that interfere with those messages. Some mimic naturally occurring hormones and activate their receptors. Others block hormone receptors, change how hormones are produced or broken down, or affect the way cells respond to hormonal signals. Some can even influence gene regulation during development. Common examples include: Bisphenols (BPA, BPS, BPF): Found in certain plastics, food packaging, and can linings. Phthalates: Used in some flexible plastics, fragrances, personal care products, and food-contact materials. PFAS (per- and polyfluoroalkyl substances): A large group of persistent chemicals associated with certain nonstick, grease-resistant, water-resistant, and stain-resistant products, as well as contaminated drinking water. Parabens: Preservatives used in some cosmetics and personal care products. Certain pesticides and flame retardants: Including chemicals that were banned years ago but remain in the environment. Exposure is extremely common. These chemicals can enter our bodies through food, drinking water, air, household dust, and products that come into contact with our skin. Some can also cross the placenta or pass into breast milk. Importantly, these chemicals don't all behave the same way. Bisphenols and many phthalates are generally eliminated within hours to days, although ongoing exposure can keep their levels measurable. Some PFAS, on the other hand, can remain in the body for years. This distinction matters because it determines what exposure reduction can realistically accomplish. Can small amounts of these chemicals really affect our health? Traditionally, toxicology has relied heavily on the idea that higher doses produce greater toxicity. Hormone-disrupting chemicals introduce an additional complication: hormones themselves can produce significant biological effects at extremely low concentrations. Some endocrine disruptors have nonlinear dose-response relationships, meaning that doubling the exposure doesn't necessarily double the effect. Certain substances may also have different effects at different doses, depending on which receptors or biological pathways are involved. Timing matters, too. Exposure during fetal development, infancy, or childhood may have different consequences than the same exposure in adulthood. During these periods, hormones help guide the development of organs, reproductive systems, the brain, and metabolic pathways. Interfering with those signals may have lasting consequences, even if the chemical itself eventually leaves the body. There is also the question of combined exposures. Most research examines chemicals individually, but in real life, we're exposed to mixtures of substances that may affect overlapping hormonal pathways. None of this means that every detectable amount of an endocrine disruptor is dangerous. The presence of a chemical in your body does not, by itself, tell us whether it is causing harm. Dose, timing, duration, the specific chemical, and individual susceptibility all matter. What does the research actually show? This is where it's important to distinguish between evidence that a chemical can cause biological harm and evidence that a particular exposure did cause an individual's medical condition. Laboratory and animal studies have demonstrated that numerous endocrine-disrupting chemicals can interfere with hormone signaling and development. Human population studies have also identified associations between certain exposures and health outcomes. For example: PFAS: Some studies have linked exposure to changes in cholesterol, immune function, reproductive health, pregnancy outcomes, and certain cancers. Evidence varies substantially across individual PFAS and health outcomes. Phthalates: Prenatal exposure has been associated with preterm birth, differences in male reproductive development, and some childhood metabolic outcomes. Bisphenols: Studies have reported associations with diabetes, reproductive hormone changes, and conditions such as polycystic ovary syndrome. Certain pesticides and flame retardants: Prenatal exposures have been associated with differences in childhood cognition, attention, and neurodevelopment. These findings are important, but they require careful interpretation. Most of the human evidence comes from observational studies. Researchers measure chemical exposure and look for patterns in health outcomes. Even when an association is statistically significant, other factors may contribute to the relationship. For example, someone who frequently eats highly processed, packaged food may have higher phthalate exposure, but they may also differ in diet quality, socioeconomic circumstances, stress, and other health-related factors. Researchers try to account for these differences, but it's difficult to eliminate every potential source of confounding. There's another limitation: chemicals that leave the body quickly can be difficult to measure accurately. A single urine sample may reflect what someone ate or used recently rather than their long-term exposure. This doesn't mean we should dismiss the research. It means we need to be precise about what the evidence supports. We have enough evidence to justify reducing avoidable exposure, especially during vulnerable developmental periods. We do not have enough evidence to promise that these changes will prevent or reverse a particular disease. What actually happens when you reduce exposure? One of the most encouraging findings is that some chemical exposures can decrease relatively quickly when the source is reduced. A 2026 study published in Nature Medicine, called the PERTH trial, investigated whether changing food packaging, kitchenware, and personal care products could reduce exposure to plastic-associated chemicals. In the randomized portion of the study, 60 participants were assigned to different combinations of lower-plastic food and products over seven days. Participants who received foods produced, processed, and packaged with minimal plastic contact had measurable reductions in several urinary biomarkers compared with controls: 31.5% lower mono-n-butyl phthalate (MnBP), a marker of exposure to certain phthalates. 46.7% lower monobenzyl phthalate (MBzP), another phthalate metabolite. 58.5% lower total measured bisphenols. Changing personal care products alone had a narrower effect, reducing one phthalate marker without significantly changing bisphenol levels. These results suggest that food-related exposures are an important target for reducing certain plastic-associated chemicals. There are some important caveats, though. The study was small, lasted only one week, and measured changes in chemical biomarkers rather than long-term clinical outcomes. It also provided participants with carefully sourced low-plastic foods, which may not be practical or affordable for most households. The study demonstrated that changing exposures can change what we measure in the body. It did not demonstrate that those changes improve health. That's an important distinction, but it doesn't make the findings meaningless. Reducing unnecessary exposure is a reasonable preventive measure, even while we continue studying its long-term benefits. So what about detoxing? This is where the science and the wellness industry diverge. The concept of reducing exposure is legitimate. The idea that your body needs a commercial detox program to remove endocrine disruptors generally isn't. Your liver and kidneys continuously process and eliminate substances from the body. Certain chemicals are also eliminated through bile and stool. These processes don't require special teas, supplements, juice cleanses, or “liver support” products. For relatively short-lived chemicals like BPA and many phthalates, the most effective strategy is usually to reduce the source of exposure. Once exposure decreases, the body generally eliminates these chemicals through its normal metabolic processes. There's no good evidence that drinking detox juice, taking activated charcoal supplements, performing a liver cleanse, or using a sauna meaningfully accelerates this process or improves health outcomes related to endocrine disruptors. Some dietary compounds, including fiber and nutrients found in vegetables, may influence metabolism, the gut microbiome, or chemical handling in experimental studies. But those findings shouldn't be confused with proof that eating a particular food “flushes toxins” from the body. A varied, fiber-rich diet is beneficial for many established reasons. You don't need to justify eating vegetables by claiming that they detoxify your hormones. But aren't some chemicals much harder to eliminate? Yes. PFAS are an important exception because some remain in the body for years. Small clinical studies have found that certain medical interventions can lower blood concentrations of specific PFAS. For example, a study of highly exposed individuals found that colesevelam, a prescription medication that interrupts the recycling of bile acids through the intestine, reduced blood PFOS concentrations by approximately 38% over 12 weeks. A randomized trial involving Australian firefighters also found that regular blood or plasma donation reduced certain PFAS levels, with plasma donation producing larger reductions. These findings are scientifically interesting, but neither approach has been shown to prevent PFAS-related disease or improve clinical outcomes. Reducing a blood concentration does not automatically mean reducing a person's future risk of cancer, infertility, or other conditions. These interventions also have potential downsides, and they aren't recommended as routine treatments for PFAS exposure. For most people, the priority remains identifying and reducing ongoing exposure rather than trying to force persistent chemicals out of the body. The changes that are actually worth making You don't need to replace everything in your kitchen, buy an expensive water filtration system, or throw away all your skin care products overnight. The goal is to reduce avoidable, repeated exposures in ways that fit your life and budget. 1. Start with how you prepare and store food Food and food packaging are important sources of exposure to certain bisphenols and phthalates. In particular, chemicals can migrate from packaging or processing materials into food. Consider storing leftovers in glass or stainless steel containers and avoiding heating food in plastic whenever possible. If you frequently microwave leftovers, transferring them to a glass or ceramic dish is a relatively simple change. Reducing reliance on canned foods, highly processed packaged foods, and takeout packaging may also help reduce exposure to certain chemicals. This doesn't mean that eating canned vegetables is worse than eating no vegetables. Nutrition, convenience, affordability, and food security matter, too. If your choice is between affordable canned beans and not eating beans at all, eat the beans. 2. Pay attention to drinking water Drinking water can be an important source of PFAS exposure, particularly in communities affected by industrial contamination, firefighting foams, or certain manufacturing activities. If PFAS contamination is a concern where you live, an appropriately certified activated carbon or reverse osmosis filtration system may reduce exposure. Not every filter removes PFAS equally well, so checking certification and maintenance requirements matters. For people without a known water contamination problem, there's no reason to assume that an expensive filtration system is automatically necessary. 3. Make simple changes to personal care products Some fragrances and personal care products contain phthalates or other chemicals with potential endocrine effects. Choosing fragrance-free products and reducing the number of heavily scented products you use may help limit some exposures. Fragrance-free and unscented aren't necessarily the same thing. A product labeled “unscented” may still contain masking fragrance ingredients. You also don't need to replace every product you own with something marketed as “clean,” “natural,” or “non-toxic.” Those terms aren't reliable guarantees of safety. 4. Reduce household dust Household dust can contain flame retardants, plastic-associated chemicals, pesticides, and other environmental contaminants. Damp-dusting surfaces, wet-mopping floors, and washing hands before eating can help reduce contact with contaminated dust. These measures are particularly useful in households with young children, who spend more time close to the floor and frequently put their hands in their mouths. 5. Be skeptical of marketing labels “BPA-free” doesn't necessarily mean free of endocrine-disrupting chemicals. Some manufacturers have replaced BPA with chemically similar alternatives such as BPS or BPF, which may have their own endocrine effects. Likewise, “natural” doesn't mean harmless, and “chemical-free” doesn't mean anything scientifically meaningful. Water, oxygen, and every ingredient in your moisturizer are chemicals. It's more useful to think about the specific substance, route of exposure, and available safety data than to divide products into vaguely defined categories of “toxic” and “clean.” Why pregnancy and early childhood deserve special attention If there's one period when reducing avoidable chemical exposures may matter most, it's before conception, during pregnancy, and throughout early childhood. During fetal development, hormones help orchestrate the formation of organs and the development of the nervous and reproductive systems. Certain chemicals can cross the placenta, meaning that maternal exposure can also become fetal exposure. Studies have linked prenatal exposure to some PFAS, phthalates, bisphenols, and pesticides with outcomes such as preterm birth, differences in birth weight, and developmental changes. These associations are generally modest, and observational studies cannot establish causation on their own. Still, the potential consequences of disrupting development are significant, and some developmental changes may not be reversible later in life. This is why ACOG recommends discussing environmental and occupational exposures before pregnancy when possible. That discussion might include drinking water quality, workplace exposures, pesticide use, food storage practices, and the home environment. Certain occupations, including agriculture, manufacturing, salons, dry cleaning, and some health care settings, may involve exposures requiring more specific assessment. For someone planning a pregnancy, reducing exposure beforehand is particularly relevant for persistent chemicals such as PFAS, which may remain in the body for years. For short-lived chemicals such as many phthalates and bisphenols, changes made during pregnancy can still reduce ongoing exposure. None of this means that someone who has already been exposed has harmed their future child, or that a pregnant person needs to eliminate every possible chemical exposure. Pregnancy is already a period of enormous pressure and conflicting advice. Environmental health counseling should help people make informed choices, not create another source of guilt. What about breastfeeding? Some endocrine-disrupting chemicals, including PFAS, can be detected in breast milk. This sometimes leads to understandable concern about whether breastfeeding is safe. The important context is that detecting a chemical in breast milk does not establish that the concentration causes clinical harm. Research on infant outcomes is limited, and exposure can also occur through formula, its packaging, and the water used to prepare it. The CDC and other major health organizations continue to recommend breastfeeding when possible and desired. Based on current evidence, the established benefits generally outweigh the potential risks from PFAS exposure through breast milk. The appropriate response is to reduce significant sources of exposure when possible, not to discourage breastfeeding or recommend unnecessary testing of breast milk. Should you get tested for endocrine disruptors? For most people, routine testing for endocrine-disrupting chemicals isn't necessary or particularly helpful. A urine test for BPA or phthalate metabolites may tell you something about recent exposure, but it generally cannot establish whether that exposure has caused a health problem or predict whether you will develop one. PFAS testing is somewhat different. In 2022, the National Academies of Sciences, Engineering, and Medicine recommended offering PFAS blood testing to people with a history suggesting elevated exposure, such as contaminated community drinking water or certain occupational exposures. Their clinical guidance uses the combined blood concentration of seven specific PFAS to help determine whether additional health monitoring may be appropriate. Testing still has limitations. It doesn't measure every PFAS, cannot determine whether a particular illness was caused by exposure, and doesn't provide a straightforward treatment target. For people with a known or suspected high exposure, testing may help guide medical follow-up. For someone without a concerning exposure history, broad chemical testing panels are unlikely to provide actionable information. If you're concerned about a particular exposure, a detailed history and discussion with your primary care clinician is often a better starting point than ordering a commercial toxin panel. The bigger problem: we can't shop our way out of environmental pollution There's an important limitation to all of this advice. Chemical exposure isn't distributed equally. People living near industrial facilities, heavily polluted roads, contaminated water systems, or certain workplaces may face greater exposures than someone whose primary concern is which food storage containers to buy. Income, housing quality, occupation, and environmental policy all influence exposure. Many of the people facing the greatest risks also have the fewest resources to avoid them. It's easy to tell someone to eat fresh organic food, replace their cookware, install water filters, and buy new furniture. It's much harder to do those things when you're managing a tight budget, working multiple jobs, or living somewhere with limited access to affordable food. And even people who can afford every recommended product swap cannot eliminate chemicals from their air, water, food supply, or broader environment through individual purchasing decisions alone. That requires better chemical safety testing, more transparent labeling, pollution prevention, and public health protections. We should be careful not to turn a systemic environmental health problem into another individual responsibility, particularly one that requires people to spend money they may not have. The bottom line Endocrine-disrupting chemicals are not imaginary, and concerns about their potential health effects are supported by substantial scientific research. But the existence of a real environmental health risk doesn't validate every product or intervention marketed as a solution. We know that certain exposures are associated with meaningful health risks. We know that some relatively simple changes, particularly around food packaging and preparation, can lower measurable exposure to specific chemicals. We also know that periods such as pregnancy and early childhood deserve particular attention. What we don't yet know is how much those changes alter long-term disease risk for an individual, whether reducing exposure reverses established health effects, or whether interventions intended to accelerate chemical elimination provide meaningful clinical benefits. You don't need a detox protocol. You don't need to replace everything you own. And you don't need to be afraid of every chemical you encounter. Start with changes that are practical, affordable, and sustainable. Focus on reducing unnecessary exposure rather than trying to achieve the impossible goal of eliminating it completely. References: Endocrine Society: Endocrine-Disrupting Chemicals (2025). The scientific basis for EDCs and recommendations to reduce exposure. Nature Medicine: The PERTH Randomized Trial (2026). Evidence that a lower-plastic diet can reduce urinary biomarkers within seven days. ACOG: Reducing Prenatal Exposure to Toxic Environmental Agents. Preconception and pregnancy counseling recommendations. National Academies: Guidance on PFAS Exposure, Testing, and Clinical Follow-Up (2022). Testing recommendations and interpretation of PFAS concentrations. CDC/ATSDR: Breastfeeding and PFAS. Guidance supporting continued breastfeeding. Clinical crossover study of bile acid sequestrants and PFAS elimination (2025). Preliminary findings on colesevelam and PFAS concentrations. JAMA Network Open: Blood and Plasma Donation for PFAS Reduction (2022). Randomized trial in firefighters. EPA: Identifying Drinking Water Filters Certified to Reduce PFAS. Practical consumer guidance for water filtration.

One of the most common conversations I have in clinic starts with a simple request: "Can we just check all of my hormones?" Sometimes it's because someone has been feeling exhausted for months. Sometimes they're struggling with weight changes, brain fog, anxiety, acne, low libido, or hair loss. Other times, they don't have a specific symptom at all—they've simply heard from friends, podcasts, or social media that it's a good idea to "check your hormones" every so often. It's an understandable question. Hormones influence nearly every system in our bodies, and when something doesn't feel quite right, it seems logical to wonder whether they might be the cause. The challenge is that hormones don't behave the way most people think they do. Hormones are constantly changing Unlike cholesterol or blood sugar, hormones are not meant to stay at one stable level. Many hormones rise and fall throughout the day. Others fluctuate dramatically over the course of the menstrual cycle. They can change in response to stress, illness, sleep, exercise, medications, pregnancy, weight changes, and even whether you've recently eaten. For women who are still menstruating, estrogen and progesterone can vary enormously from one week to the next—and sometimes from one day to the next. Testosterone levels are highest early in the morning and naturally decline as the day goes on. Cortisol follows its own predictable daily rhythm, peaking shortly after waking and gradually falling throughout the day. In other words, a hormone level measured at one moment in time is just that: a snapshot. Without understanding the context in which that snapshot was taken, the number often doesn't tell us very much. This is one of the biggest reasons why broad hormone panels can be surprisingly difficult to interpret. More testing doesn't always lead to more answers It's easy to assume that ordering more laboratory tests will increase our chances of finding the problem. In reality, the opposite is often true. Every laboratory test has a "normal" reference range, usually defined as the values seen in about 95% of healthy individuals. That means approximately one out of every twenty healthy people will have a result that falls just outside the normal range despite having no underlying disease. When we order ten or fifteen hormone tests at once, the chances of finding at least one slightly abnormal result become remarkably high. Most of the time, that abnormality doesn't represent a hormone disorder at all. It's simply normal biological variation. Unfortunately, once an abnormal result appears on a lab report, it can be difficult to ignore. That single number may lead to repeat blood work, imaging studies, specialist referrals, or additional testing—all without bringing us any closer to understanding why someone doesn't feel well. Large studies of direct-to-consumer wellness panels have demonstrated exactly this problem. These broad panels frequently identify incidental abnormalities that generate additional testing but rarely uncover meaningful disease in otherwise healthy individuals. What doctors are actually trying to diagnose One phrase that has become incredibly popular online is "hormone imbalance." Although it sounds like a medical diagnosis, it really isn't one. In medicine, we're usually looking for specific endocrine disorders such as hypothyroidism, polycystic ovary syndrome (PCOS), hyperprolactinemia, primary ovarian insufficiency, hypogonadism, Cushing syndrome, or adrenal insufficiency. Each of these conditions has characteristic symptoms, physical examination findings, and carefully validated testing strategies. We don't diagnose them by checking every hormone available. We diagnose them by listening carefully to the patient's story, performing an examination, and choosing the laboratory tests that best answer the clinical question we're asking. That's why the conversation in my office often starts with a different question than patients expect. Instead of asking, "Which hormones should we check?" I usually ask, "What are you hoping the hormone tests will explain?" The answer to that question is often much more revealing. "I just don't feel good." This is perhaps the hardest situation—and one that every primary care physician encounters regularly. Feeling unwell is absolutely real. Fatigue, brain fog, poor concentration, weight changes, sleep disturbances, low motivation, and generalized malaise can have an enormous impact on quality of life. The difficulty is that these symptoms are not unique to hormone disorders. They can be caused by poor sleep, iron deficiency, vitamin deficiencies, depression, anxiety, ADHD, medication side effects, diabetes, chronic infections, autoimmune diseases, pregnancy, long COVID, ME/CFS, thyroid disease, and dozens of other medical conditions. Hormone disorders certainly belong on that list, but they are only one possibility among many. The challenge for clinicians is not deciding whether hormones could be involved—they certainly can be. The challenge is deciding whether the pattern of symptoms makes a particular hormone disorder likely enough that testing will provide meaningful answers. That distinction matters because the usefulness of any medical test depends on the likelihood that the condition is actually present before the test is ordered. The right test depends on the right question When someone has irregular or absent menstrual periods, hormone testing is often an important part of the evaluation. Depending on the situation, this may include pregnancy testing, thyroid function, prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol. Someone with excessive facial hair, severe acne, or signs of elevated androgen levels may benefit from measurements of testosterone, DHEAS, or 17-hydroxyprogesterone. A man with decreased libido, loss of morning erections, infertility, or unexplained osteoporosis may appropriately undergo evaluation for testosterone deficiency. Even then, the diagnosis cannot be made from a single blood test. Current guidelines recommend obtaining two separate early-morning testosterone measurements because levels naturally fluctuate throughout the day. Each of these situations begins with a clinical question. The laboratory tests are chosen because they help answer that question—not because they provide a general assessment of hormonal health. What about estrogen, progesterone, cortisol, or AMH? These are some of the most commonly requested hormone tests, but they're also among the easiest to misunderstand. Random estrogen and progesterone levels are rarely helpful outside of specific reproductive or endocrine evaluations because they vary so dramatically during the menstrual cycle. Random cortisol measurements generally cannot diagnose either adrenal insufficiency or Cushing syndrome. Those conditions require carefully timed testing using methods that have been validated for those specific diseases. Trends in cortisol, similar to all of the other hormones, are much more important than single numbers. Anti-Müllerian hormone (AMH) has become increasingly popular through fertility marketing, yet professional organizations specifically recommend against using a single AMH level to predict natural fertility or estimate when menopause will occur in women who are not undergoing infertility evaluation. In each case, the issue isn't that the tests are "bad." It's that they're extremely useful only when they're being used to answer the right clinical question. The influence of social media Over the past several years, I've noticed a significant increase in patients requesting hormone testing after seeing content online. Many of these videos suggest that common symptoms—fatigue, weight gain, anxiety, acne, headaches, difficulty concentrating, poor sleep, or low motivation—are all signs of hormone imbalance. There's a small grain of truth in that message. Hormone disorders can absolutely cause many of those symptoms. The problem is that those same symptoms are also associated with dozens of other conditions, many of which are far more common. When every nonspecific symptom is attributed to hormones, it's easy to overlook the broader picture. Good medical care doesn't begin by assuming a diagnosis. It begins by understanding the whole person. The conversation I hope every patient hears When patients ask me to check their hormones, I don't want them to feel dismissed. Their symptoms are real, and their concerns deserve careful attention. Instead, I usually explain that hormones are different from many other laboratory tests because they're constantly changing. Without a specific reason to measure them, broad hormone panels are much more likely to generate confusing results than useful ones. Then we return to what matters most. What symptoms are you experiencing? When did they begin? What else has changed? What are you most worried about? Those answers almost always tell us far more than a large hormone panel ever could. Sometimes they lead us toward endocrine testing. Sometimes they point us in an entirely different direction. Either outcome is valuable because it brings us closer to understanding what's actually happening. Medicine isn't about ordering every available test. It's about asking thoughtful questions, interpreting results in context, and using evidence to guide decisions that genuinely improve people's health. Learn More Professional Guidelines Endocrine Society. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. American Urological Association. Testosterone Deficiency Guideline. American College of Obstetricians and Gynecologists. The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care. U.S. Preventive Services Task Force. Screening for Thyroid Dysfunction in Nonpregnant, Asymptomatic Adults. Endocrine Society Clinical Practice Guidelines on hirsutism, functional hypothalamic amenorrhea, and related endocrine disorders. Selected Evidence Studies evaluating direct-to-consumer wellness panels consistently demonstrate high rates of false-positive and incidental findings, often leading to unnecessary downstream testing in healthy individuals. Research on hormone assay performance highlights substantial biologic variability related to circadian rhythm, menstrual cycle phase, assay methodology, and physiologic state, supporting guideline recommendations for targeted rather than routine hormone testing.

Insurance denials for GLP-1 medications have become one of the biggest barriers to evidence-based obesity care. Here's what's actually happening—and what both patients and clinicians can do about it. If you're a patient who has been told you "need to lose weight" for years, finally found a treatment that works, and then discovered your insurance won't cover it, you're not alone. If you're a physician who spends hours writing prior authorizations and appeals only to receive another denial, you're not imagining things either. Over the past several years, insurance companies have dramatically expanded restrictions on GLP-1 medications—including semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®)—despite an explosion of evidence showing that these medications improve not only weight, but diabetes, cardiovascular disease, obstructive sleep apnea, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), and overall mortality. The frustrating part? Many denials have little to do with whether the medication is medically appropriate. The insurance landscape changed almost overnight Several recent studies paint a striking picture. Between 2023 and 2025, Medicare Part D plans rapidly expanded prior authorization requirements for GLP-1 medications. What had been required by fewer than 15% of plans in 2023 became nearly universal by 2025. At the same time, patient cost-sharing increased substantially as many plans shifted from fixed copays to percentage-based coinsurance, dramatically increasing monthly out-of-pocket costs. Even more striking is what plans choose to cover. Medicare covers diabetes indications for semaglutide and tirzepatide through the vast majority of Part D plans, yet coverage remains essentially nonexistent when the exact same medication is prescribed for FDA-approved obesity-related indications such as obesity itself or obstructive sleep apnea. In other words: the medication isn't being denied because it doesn't work; it's being denied because of how the insurance benefit was designed. A denial isn't always a medical decision One of the biggest misconceptions is that every denial means an insurance company believes the medication is unnecessary. That's often not true. There are two fundamentally different reasons a GLP-1 prescription may be denied. 1. The medication is excluded from the benefit. This is especially common for anti-obesity medications. Many employer-sponsored plans simply exclude weight-loss medications altogether. Medicare Part D has historically excluded medications prescribed solely for weight loss because of federal statute—not because of medical evidence. If the medication is excluded, writing a longer appeal letter usually doesn't change the outcome. This is primarily a policy problem, not a medical one. 2. The medication is covered—but the insurer says you haven't met its requirements. These denials usually involve: Prior authorization Step therapy Documentation requirements Dose restrictions Reauthorization criteria Diagnosis mismatch These denials are often appealable. The key is knowing which type of denial you're dealing with before spending hours writing another medical necessity letter. The rise of non-clinical barriers Increasingly, insurers are adding requirements that go far beyond confirming that a medication is appropriate. These requirements often function less like medical review and more like administrative barriers designed to reduce utilization. "Complete six months of Wellvolution first." Many insurers now require participation in proprietary lifestyle programs—such as Wellvolution—before approving GLP-1 therapy. At first glance, this sounds reasonable. Lifestyle modification is important, but there's an important distinction. Current obesity guidelines recommend behavioral treatment and medication together, not one followed by the other after an arbitrary waiting period. Requiring six months of an insurer-selected commercial program raises several concerns. It may: Duplicate treatment the patient has already completed with their own physician, dietitian, therapist, or diabetes educator. Delay treatment for a progressive chronic disease. Disproportionately disadvantage patients with disabilities, caregiving responsibilities, demanding work schedules, limited internet access, or prior negative experiences with weight-loss programs. Ignore the reality that many patients have already spent years attempting lifestyle interventions before seeking medication. Perhaps most importantly, there is little published evidence demonstrating that requiring a specific proprietary six-month program improves outcomes compared with clinician-directed obesity care. "Your doctor isn't ABOM certified." Some insurers have begun requiring obesity medications to be prescribed by physicians with certification from the American Board of Obesity Medicine (ABOM). ABOM certification is an excellent credential that reflects additional expertise in obesity medicine. It is not, however, a requirement for medical licensure or board certification. Many highly experienced physicians—including family physicians, internists, pediatricians, and even endocrinologists—are not ABOM-certified. That's because ABOM certification requires: Additional obesity-specific continuing medical education A separate certification examination Significant financial cost Time away from clinical practice Ongoing maintenance requirements Many physicians who safely prescribe GLP-1 medications every day have never pursued this voluntary credential—not because they lack expertise, but because they lack the time, money, or protected educational leave to obtain it. If a patient meets FDA criteria, the medication is appropriate, and a board-certified physician is prescribing within their scope of practice, denying treatment solely because that physician lacks a voluntary certification becomes difficult to justify from a patient-care perspective. Importantly, there is little published evidence that restricting prescribing to ABOM diplomates improves safety or outcomes. These barriers disproportionately affect the patients who need treatment most Administrative hurdles are never distributed equally. Patients with stable employment, flexible schedules, transportation, reliable internet, and financial resources often find ways through. Others don't. Every additional form, required appointment, mandatory program, or appeal disproportionately affects patients who already face barriers to care. Researchers have increasingly raised concerns that expanding prior authorization requirements may widen existing health disparities by delaying treatment for patients at highest cardiometabolic risk. What physicians can do Although clinicians cannot change benefit design, we can make the process more effective. First, identify the actual denial reason. Never accept "denied" as sufficient information. Obtain the actual denial letter. Determine whether the problem is: Benefit exclusion Missing documentation Prior authorization criteria Step therapy Quantity limits Diagnosis mismatch Administrative error Every one of these requires a different response. Document prospectively. Rather than reconstructing the chart after a denial, include common prior authorization requirements during the initial visit: BMI and weight trend Weight-related complications Previous medications Prior lifestyle interventions Contraindications Functional impairment FDA-approved indication Planned follow-up Percentage of body weight lost while on therapy if applicable Specific documentation saves time later. Appeal the actual reason—not obesity in general. The strongest appeal directly addresses every criterion the insurer says wasn't met. Instead of explaining why GLP-1 medications are effective, explain exactly where the patient's documentation satisfies the insurer's own policy. Sometimes the appeal should challenge the policy itself When an insurer requires six months of a proprietary lifestyle program, consider asking: What evidence supports this exact requirement? Why is previous clinician-directed treatment insufficient? Can prior participation satisfy the requirement? Can participation occur concurrently with medication? Is a disability accommodation available? Similarly, if ABOM certification is required: Request the exact written policy. Ask whether board-certified endocrinologists, family physicians, internists, or obesity specialists without ABOM certification qualify. Request the evidence showing that the requirement improves patient safety. Ask how patients are expected to obtain care if no qualifying clinician is reasonably available. These are reasonable questions. The burden should be on the insurer to demonstrate that additional restrictions improve patient outcomes—not simply reduce utilization. The bigger issue Physicians should absolutely continue advocating for individual patients. But increasingly, this has become a systems problem rather than an individual documentation problem. Professional organizations have begun calling for: Transparent prior authorization criteria Elimination of unsupported step therapy requirements Coverage consistent with FDA-approved indications Recognition of obesity as a chronic disease Continuity protections for patients already benefiting from therapy Reduced administrative burden Public reporting of denial and appeal rates Coverage decisions based on evidence rather than arbitrary administrative barriers The bottom line GLP-1 medications are among the most effective treatments ever developed for obesity and related metabolic disease. The challenge is no longer simply determining who would benefit. Increasingly, it's determining who can actually get access. Patients deserve coverage decisions based on medical evidence—not unnecessary administrative obstacles. Physicians should continue writing strong documentation and thoughtful appeals, but we should also recognize when the problem isn't our charting. Sometimes the barrier isn't medicine; it's the insurance policy. Learn More Peer-reviewed literature Liu X, et al. Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open. 2025. Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. JAMA. 2025. Shahzad M, et al. GLP-1 Prescriptions for Weight Loss by Differences in Employer-Sponsored Insurance Coverage. JAMA Health Forum. 2026. Sarpatwari A, et al. Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Patient Characteristics. JAMA Health Forum. 2025. Pearson SD, et al. Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions. 2025. Herges JR, et al. Navigating Cost and Access Barriers for Medications in the Treatment of Obesity. 2025. American Medical Association. Private Insurance Coverage of Anti-Obesity Medications. Council on Medical Service. 2026. Healthcare.gov. Internal and External Insurance Appeals. Legal references Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Social Security Act §1927(d)(2).

Many people assume that abnormal uterine bleeding is simply "part of having a uterus." In reality, changes in menstrual bleeding can sometimes be the first sign of an underlying medical condition that deserves evaluation. The good news is that most abnormal bleeding is not caused by cancer. It is often related to hormonal changes, benign growths such as fibroids or polyps, medications, or other treatable conditions. However, because serious causes can occasionally present in the same way, it's important to approach abnormal bleeding thoughtfully rather than dismissing it. What Counts as Abnormal Uterine Bleeding? Abnormal uterine bleeding (AUB) refers to bleeding from the uterus that differs from your usual pattern. This may include: Periods that are much heavier than normal Bleeding that lasts longer than expected Bleeding between periods Very frequent or very infrequent periods Bleeding after sex Bleeding after menopause Bleeding that causes anemia, dizziness, or significantly affects daily life Everyone's "normal" is different. The important question is whether your bleeding has changed from your usual pattern or is interfering with your health or quality of life. The First Questions Your Clinician Will Ask The evaluation begins long before any tests are ordered. Your clinician will want to understand: When the bleeding started How heavy it is (including flooding, large clots, or bleeding through clothing) How long it lasts Whether your cycles have become irregular Whether you're experiencing pelvic pain, fever, unusual discharge, or pain with intercourse Whether you could be pregnant What medications or hormones you're taking Whether you've recently started, stopped, or missed hormonal medications Whether you have symptoms of anemia such as fatigue, dizziness, or shortness of breath Whether you have risk factors for uterine cancer or inherited bleeding disorders These questions help determine which causes are most likely and which tests will actually be useful. Pregnancy Comes First If pregnancy is biologically possible, the first step is almost always a pregnancy test. Pregnancy-related bleeding follows a completely different diagnostic pathway than non-pregnancy-related bleeding. Even people using contraception or those who believe pregnancy is unlikely may still be tested because early pregnancy complications can occasionally be life-threatening. Is It an Emergency? Most abnormal bleeding does not require emergency care. However, seek immediate medical attention if you have: Heavy bleeding causing fainting or near-fainting Severe dizziness Chest pain or shortness of breath Rapid heartbeat with heavy bleeding Bleeding that soaks through multiple pads per hour for several hours Severe pelvic pain, especially during pregnancy Signs of severe anemia Understanding the Causes: The PALM-COEIN System Gynecologists use an internationally recognized system called PALM-COEIN to organize the possible causes of abnormal uterine bleeding. Structural causes (things you can often see on imaging) P – PolypsSmall growths inside the uterus or cervix. A – AdenomyosisThe uterine lining grows into the muscular wall of the uterus. L – Leiomyomas (Fibroids)Benign tumors made of muscle tissue. M – Malignancy and HyperplasiaPrecancerous changes or cancer of the uterine lining. Non-structural causes C – CoagulopathyBleeding disorders such as von Willebrand disease. O – Ovulatory dysfunctionIrregular ovulation, common with PCOS, thyroid disease, stress, significant weight changes, adolescence, and perimenopause. E – Endometrial causesProblems with the uterine lining itself despite normal hormones and anatomy. I – IatrogenicBleeding caused by medications or medical treatments, including hormonal contraception, menopausal hormone therapy, tamoxifen, or anticoagulants. N – Not otherwise classifiedLess common causes that don't fit into the other categories. Blood Tests Not everyone needs extensive laboratory testing. Depending on your symptoms, your clinician may recommend: Complete blood count (CBC) to look for anemia Ferritin to evaluate iron stores Pregnancy testing Thyroid testing (when indicated) Testing for bleeding disorders if your history suggests one Other hormone testing only when clinically appropriate Testing should be guided by your history rather than performed routinely for everyone. Ultrasound and Biopsy Answer Different Questions A common misconception is that an ultrasound alone can rule out cancer. This is NOT the case. These tests provide different information. Ultrasound helps identify: Fibroids Polyps Ovarian cysts Adenomyosis Other structural abnormalities Endometrial biopsy evaluates: The cells lining the uterus Endometrial hyperplasia (precancer) Endometrial cancer Because these tests answer different questions, some patients need one, while others benefit from both. If bleeding continues despite a normal biopsy, additional evaluation may still be necessary because a blind biopsy can occasionally miss focal abnormalities such as polyps. A Special Note About Perimenopause Perimenopause is one of the most common times for bleeding patterns to change. Although hormonal fluctuations often explain irregular bleeding during this stage of life, not every episode should automatically be blamed on menopause. Risk factors, symptoms, age, hormone therapy, and individual circumstances determine whether additional evaluation—including imaging or biopsy—is appropriate. Importantly, endometrial thickness should not be used by itself to rule out cancer in premenopausal or perimenopausal patients. Unlike after menopause, the uterine lining naturally changes throughout the menstrual cycle, making thickness measurements much less reliable. Bleeding After Menopause Any bleeding after menopause deserves medical evaluation. While many causes are benign—including vaginal thinning, polyps, or hormone therapy—postmenopausal bleeding can also be an early sign of endometrial cancer. Early evaluation greatly improves the chance of detecting problems while they are highly treatable. Special Situations Some people require a slightly different approach, including: Adolescents (where irregular cycles can be normal for the first 2–3 years after the first menstrual period) People with inherited bleeding disorders Individuals taking blood thinners Those with prior cesarean deliveries (who may develop cesarean scar defects) People using hormonal contraception or menopausal hormone therapy Transgender and gender-diverse patients, whose evaluation depends on their anatomy, hormone regimen, pregnancy potential, and individual goals Every evaluation should be individualized rather than based on assumptions. Trauma-Informed and Inclusive Care Matters Pelvic bleeding evaluations can feel vulnerable or even frightening. A good evaluation should include: Shared decision-making Trauma-informed care Pain management during procedures when appropriate Respect for your gender identity and reproductive goals Clear explanations about why tests are being recommended Reliable follow-up for imaging and biopsy results You deserve to understand what is happening and to participate in decisions about your care. When Should You See a Healthcare Professional? Schedule an evaluation if you experience: Bleeding between periods Very heavy periods Bleeding lasting more than about a week Bleeding after menopause Bleeding after sex New irregular bleeding Symptoms of anemia Bleeding that is significantly different from your usual pattern Most causes of abnormal uterine bleeding are treatable. Getting evaluated early can help identify the cause, improve symptoms, prevent complications such as iron deficiency, and—when necessary—detect serious conditions as early as possible. Learn More American College of Obstetricians and Gynecologists. (2012). Diagnosis of abnormal uterine bleeding in reproductive-aged women (Practice Bulletin No. 128). Obstetrics & Gynecology, 120(1), 197–206. https://doi.org/10.1097/AOG.0b013e318262e320 Dreisler, E., Frandsen, C. S., & Ulrich, L. G. (2024). Perimenopausal abnormal uterine bleeding. Maturitas, 188, 108054. https://doi.org/10.1016/j.maturitas.2024.108054 Jain, V., Munro, M. G., & Critchley, H. O. D. (2023). Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO Systems 1 and 2. International Journal of Gynecology & Obstetrics, 163(Suppl. 2), 3–17. https://doi.org/10.1002/ijgo.14926 Wouk, N., & Helton, M. (2019). Abnormal uterine bleeding in premenopausal women. American Family Physician, 99(7), 435–443. American College of Obstetricians and Gynecologists. Patient education resources on abnormal uterine bleeding and heavy menstrual bleeding: https://www.acog.org/womens-health International Federation of Gynecology and Obstetrics (FIGO). Classification systems for abnormal uterine bleeding: https://www.figo.org

One of the most common misconceptions in healthcare is the assumption that a patient's ability to communicate is stable. Many clinicians unconsciously judge a patient's cognitive status, insight, or symptom severity based on how easily they can answer questions during a visit. For many patients, this assumption is wrong. Communication is often state-dependent. Stress, pain, trauma, sensory overload, autonomic dysfunction, fatigue, cognitive overload, migraine, hypoglycemia, and many neurodevelopmental or neurologic conditions can temporarily reduce a person's ability to access spoken language—even when their understanding, intelligence, and decision-making remain intact. This phenomenon is well recognized in augmentative and alternative communication (AAC), where some individuals are "part-time" AAC users. They may speak fluently much of the time but rely on typing, text, or other communication methods when speech becomes unreliable or inaccessible. The same principle applies far beyond AAC. Patients with trauma histories, PTSD, dissociation, autism, ADHD, ME/CFS, Long COVID, dysautonomia, functional neurologic disorders, aphasia, migraine, or other conditions may experience periods in which spoken communication becomes substantially more difficult. This does not necessarily mean they are unwilling to answer questions. It does not mean they are exaggerating. It does not mean they are cognitively impaired. It does not mean they "must not be that anxious" because they spoke normally twenty minutes ago. Rather, speech itself has become a limited resource. What this can look like A patient may: Become noticeably quieter or stop speaking altogether. Take significantly longer to answer questions. Lose words or substitute incorrect words. Default to short, automatic responses such as "I'm fine" despite wanting to communicate something much more complex. Know exactly what they want to say but be unable to produce the words. Type, write, gesture, or communicate far more effectively than they can speak. Experience marked fluctuations over the course of a single visit. These fluctuations often correlate with increasing cognitive load, emotional activation, sensory input, physical symptoms, or fatigue. Why this happens Speech is an extraordinarily complex task requiring coordination of attention, working memory, language formulation, executive function, motor planning, and social processing. During states of significant physiologic or psychological stress, the brain prioritizes survival over efficient communication. Trauma activation, autonomic dysregulation, cognitive fatigue, and sensory overload can all reduce access to fluent speech without reducing comprehension or intelligence. The patient has not "forgotten" how to talk. Their brain temporarily has reduced access to spoken language. Common clinical mistakes Unfortunately, patients frequently report experiences such as: "You were talking earlier, so clearly you can talk now." "If you can answer that question, you can answer the rest." "You're refusing to participate." "You're just being difficult." "You're too articulate to have communication difficulties." These statements misunderstand how communication works. Speech ability is not binary. It is dynamic. A patient may move between fluent conversation and near-complete inability to speak over minutes or hours depending on their physiologic and psychological state. What clinicians can do instead When communication becomes more difficult: Slow the pace of the encounter. Ask one question at a time. Allow significantly longer processing time before repeating or rephrasing. Offer yes/no questions when appropriate. Accept typed responses, written notes, patient portal messages, or AAC devices. Reduce unnecessary sensory input whenever possible. Avoid interpreting reduced speech as reduced understanding. Ask, "Would another way of communicating be easier right now?" Most importantly, believe patients when they describe fluctuations in their communication abilities. The key principle Communication modality should be treated like any other functional accommodation. We already recognize that a patient may need a wheelchair despite being able to walk short distances, or may need supplemental oxygen despite appearing comfortable at rest. Similarly, a patient may sometimes communicate effectively through speech and at other times communicate far more accurately through writing, typing, gestures, or AAC. The goal is not to determine whether a patient "can" speak. The goal is to identify the communication method that allows the patient to express themselves most accurately and with the least cognitive and physiologic cost. When clinicians recognize communication as state-dependent rather than fixed, they improve diagnostic accuracy, reduce patient distress, strengthen therapeutic relationships, and make healthcare more accessible for many patients whose communication needs have historically been misunderstood. Learn More Augmentative & Alternative Communication (AAC) AssistiveWare. Supporting communication for part-time AAC users.https://www.assistiveware.com/learn-aac/support-communication-for-part-time-aac-users An excellent introduction to the concept that communication needs are not static. Describes how many people move between spoken language and AAC depending on fatigue, stress, illness, cognitive load, or other factors. AssistiveWare. Part-time AAC use: What does it mean and why does it matter?https://download.assistiveware.com/assistiveware/files/part-time-aac-use-what-does-it-mean-and-why-does-it-matter.pdf Explains why communication should be viewed as dynamic rather than binary ("speaking" versus "non-speaking") and discusses concepts such as unreliable and intermittent speech. Trauma & Neurobiology van der Kolk BA. The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. New York: Viking; 2014. A highly accessible overview of how traumatic stress alters cognition, language, autonomic function, and emotional regulation. Introduces the concept that language access may diminish during trauma activation. Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research—past, present, and future. Biological Psychiatry. 2006;60(4):376-382. Reviews functional neuroimaging findings demonstrating altered activation of brain regions involved in emotion regulation, executive function, and language during traumatic stress. Polyvagal Theory & Autonomic State Porges SW. The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-Regulation. New York: W.W. Norton; 2011. Although aspects of Polyvagal Theory remain debated, it has influenced trauma-informed care by emphasizing how autonomic state affects social engagement and communication. Autism & State-Dependent Communication American Speech-Language-Hearing Association (ASHA). Augmentative and Alternative Communication (AAC).https://www.asha.org/practice-portal/professional-issues/augmentative-and-alternative-communication/ Provides evidence-based guidance on AAC and emphasizes that communication supports should be based on functional need rather than diagnosis or permanent speech status. Autistic Self Advocacy Network (ASAN). Resources on communication accessibility.https://autisticadvocacy.org/ Offers autistic-led perspectives on fluctuating communication ability, communication access, and respecting alternative communication methods. Functional Neurological Disorder Stone J, Carson A, Hallett M. Functional neurologic disorder: Diagnosis and treatment. Neurology. (Review articles) Discusses functional neurologic symptoms, including episodic speech disturbances, emphasizing that symptoms are genuine and arise from altered brain network function rather than intentional behavior. Cognitive Fatigue & Neurologic Conditions Patients with many neurologic and systemic conditions—including ME/CFS, Long COVID, migraine, multiple sclerosis, dysautonomia, traumatic brain injury, and post-stroke syndromes—commonly report that spoken language becomes more difficult during periods of fatigue, cognitive overload, or symptom exacerbation. Although these disorders differ in mechanism, they illustrate an important shared principle: Communication ability is often state-dependent rather than fixed. Key Takeaways for Clinicians Speech is not a reliable proxy for intelligence, comprehension, insight, or decision-making capacity. Communication abilities can fluctuate substantially within a single encounter. Alternative communication methods (typing, writing, AAC, gestures, text) are accommodations—not evidence of malingering or poor effort. Patients are often the best experts on which communication modality is most effective for them in a given moment. Respecting state-dependent communication improves diagnostic accuracy, reduces patient distress, and supports equitable, patient-centered care.